Potent, selective inhibitors to study cancer cell metabolism
Official title: Design, synthesis and biological evaluation of potent and selective pyruvate carboxylase (PC) inhibitors for studying cancer cell metabolism
Funded at New York Inst of Technology · NIH-11424849 · Data updated 2026-11-12
A researcher-led project aims to create strong, targeted molecules that block pyruvate carboxylase to help us understand and eventually treat cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Inst of Technology NIH-funded |
| Lab location | 1 site (Old Westbury, United States) |
| Project start | July 1, 2026 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $204,907 |
| NIH project number | 1R16GM159657-01A1 |
| Project ID | NIH-11424849 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals whose cancers exhibit reliance on PC-driven metabolic pathways or researchers seeking PC inhibitors for translational studies.
✕Less likely to help
Patients with cancers unlikely to depend on PC pathways may not benefit from this work.
What this research studies
This project focuses on cancer metabolism and the enzyme pyruvate carboxylase (PC), which helps cancer cells cope with limited nutrients. Using structure-guided drug design, the team will make and test small molecules that specifically inhibit PC. The work will generate a set of tool compounds to reveal how PC controls metabolism in cancer cells, with the goal of guiding future cancer therapies. The grant supports collaboration with NYIT to advance chemistry, biology assays, and preliminary biological evaluation of these inhibitors.
Why it matters
Potential benefit: If successful, patients could benefit from new research tools and potential chemotherapeutic strategies that target cancer cell metabolism.
How similar studies have gone: Previous work has linked PC to cancer metabolism, and this project aims to provide potent inhibitors to deepen understanding rather than immediate clinical application.
Where this research is happening
-
New York Inst of Technology
Old Westbury, United States Active
Researchers
- Principal investigator: Chaudhury, Subhabrata — New York Inst of Technology
- Study coordinator: Chaudhury, Subhabrata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.